VRVg 2 + VRVg 1 + Imovax Rabies + VRVg 2 + VRVg 2 + Human Rabies Immunoglobulins (HRIG)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rabies Virus
Conditions
Rabies Virus
Trial Timeline
Apr 17, 2017 → Jan 8, 2018
NCT ID
NCT03145766About VRVg 2 + VRVg 1 + Imovax Rabies + VRVg 2 + VRVg 2 + Human Rabies Immunoglobulins (HRIG)
VRVg 2 + VRVg 1 + Imovax Rabies + VRVg 2 + VRVg 2 + Human Rabies Immunoglobulins (HRIG) is a phase 2 stage product being developed by Sanofi for Rabies Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT03145766. Target conditions include Rabies Virus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03145766 | Phase 2 | Completed |
Competing Products
20 competing products in Rabies Virus